16th Abu Dhabi Wound Care conference 2025
10. April - 11. April
ActiMaris® at the 16th Abu Dhabi Wound Care Conference 2025 – Scientific Presentation on Wound Treatment
New Insights into the Correlation Between In-Vitro and In-Vivo Efficacy of Antimicrobial Wound Therapies
Conference Highlights:
- Keynote lectures by international wound care experts
- Latest research in wound management and antimicrobial therapies
- Presentation of cutting-edge innovations in wound care
- Networking opportunities with industry leaders
Program
DOES THE IN VITRO EFFICACY PROMISE CORRELATE WITH THE IN VIVO REALITY AND CLINICAL EFFECTIVENESS IN THE LOCAL WOUND TREATMENT WITH ANTIMICROBIALS?
Our Presentation:
ActiMaris AG will present groundbreaking research on the effectiveness of the HOCl/NaOCl Redox Complex compared to other antimicrobial wound products. The study explores whether in-vitro antimicrobial efficacy truly translates into clinical performance in wound treatment.
Autor: Damir Marincic MD, Quorum Medis Institute, St.Gallen, SWITZERLAND
Aim:
Effective wound care products should demonstrate strong antimicrobial effects, biofilm disruption, anti-inflammatory action, and low cytotoxicity, often assessed via a biocompatibility index in vitro. However, in vitro tests approximate clinical conditions and may not reflect clinical outcomes. This study examines the correlation between in vitro efficacy and in vivo effectiveness across various antimicrobials.
Method:
Four in vitro studies were conducted on 15 antimicrobials (4 PHMB, 1 Octenidine, 1 PVP-I, and 9 HOCl/NaOCl products), including HOCl/NaOCl redox complex*. Concentrations and physicochemical properties varied among the tested products. In vivo, two clinical studies involving over 400 patients evaluated eight products (2 PHMB, 1 Octenidine, and 5 HOCl/NaOCl) for their antimicrobial efficacy directly in wounds.
Results / Discussion:
In vitro, HOCl/NaOCl products showed varied efficacy, dependent on concentration and physicochemical parameters. Products with 100–300 ppm demonstrated limited efficacy (log10 reduction of 1.5–3.0), whereas those with 400–800 ppm exhibited stronger efficacy (up to 5 log10) but with a slower onset (≥10 minutes). The HOCl/NaOCl redox complex* at 2000 ppm showed the highest efficacy of 6.2–7.2 log10 with a rapid onset (<1 minute), in vivo 3.4 log10 level. Other products with 100–800 ppm had lower antimicrobial efficacy (≤2.0 log10), comparable to polyhexanide product.
Conclusion:
Most products failed to translate in vitro antimicrobial results into in vivo performance. Efficacy depends not only on active substance concentration but also on specific physicochemical and colligative properties. The HOCl/NaOCl redox complex* consistently demonstrated superior efficacy both in vitro and in clinical settings, maintaining its promise in practical use.
*ActiMaris complex